IDEAYA Biosciences, Inc.

XNASHealth care

Last traded price · USD

$32.36

+3.29%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:25 IST · A quote does not mean the product is available to trade on your account.

Day's open: $31.97
Previous close: $31.33
Volume: 2.0M
Day's high: $32.36
Day's low: $31.37

In brief

IDEAYA Biosciences, Inc. is a health care company listed on Nasdaq, valued at about $3.12B.
Its shares closed at $32.36 on 4 Nov 2026, up 6.2% over the past year.
From India you can buy IDYA in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy IDEAYA Biosciences, Inc. (IDYA) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole IDYA share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade IDYA options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Below its 50- and 200-day averages
The 4 Nov 2026 close of $32.36 was 11.8% below its 50-day average ($36.71) and 4.7% below its 200-day average ($33.96). It has closed below the 200-day for 8 sessions, since 26 Oct 2026. The 50-day average crossed above the 200-day on 22 Jul 2026, 74 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
12.0 days to cover short interest
9.1M shares were sold short at the 15 Oct 2026 settlement, 10.3% of the 87.9M shares outstanding; covering them would take 12.0 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Behind SPY and its sector fund XLV over 1 year
1 month: −11.7% (SPY −1.6%, XLV +13.5%). 3 months: −10.2% (SPY −0.4%, XLV +15.5%). 1 year: +6.2% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: IDYA, SPY and XLV · as of 4 Nov 2026
35% of the way up its 52-week range
Closed at $32.36 on 4 Nov 2026: 24.2% below the 52-week high of $42.68 (25 Aug 2026) and 20.7% above the low of $26.81 (10 Jun 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Volume 2.1× its 30-session average on 4 Nov 2026
4 Nov 2026 volume of 2.0M shares was 2.1× the average of the 30 sessions before it (946.5K), as the price rose 3.3%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−11.7%

6 months+12.6%

1 year+6.2%

5 years+36.1%

Newswire

About

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

Website

Notable moves

April 24, 2023
+35.70%
September 12, 2022
+30.70%
August 15, 2022
−34.82%

Newswire

About

Website

Notable moves

April 24, 2023
+35.70%
September 12, 2022
+30.70%
August 15, 2022
−34.82%

IDEAYA Biosciences, Inc.

XNASHealth care

Last traded price · USD

$32.36

+3.29%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:25 IST · A quote does not mean the product is available to trade on your account.

Day's open: $31.97
Previous close: $31.33
Volume: 2.0M
Day's high: $32.36
Day's low: $31.37

In brief

IDEAYA Biosciences, Inc. is a health care company listed on Nasdaq, valued at about $3.12B.
Its shares closed at $32.36 on 4 Nov 2026, up 6.2% over the past year.
From India you can buy IDYA in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy IDEAYA Biosciences, Inc. (IDYA) shares from India?

Do I need the price of a whole IDYA share to invest?

How much can I invest in US stocks in a year?

Can I trade IDYA options or futures?

Insights

Quotes run fifteen minutes behind.

Below its 50- and 200-day averages
The 4 Nov 2026 close of $32.36 was 11.8% below its 50-day average ($36.71) and 4.7% below its 200-day average ($33.96). It has closed below the 200-day for 8 sessions, since 26 Oct 2026. The 50-day average crossed above the 200-day on 22 Jul 2026, 74 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
12.0 days to cover short interest
9.1M shares were sold short at the 15 Oct 2026 settlement, 10.3% of the 87.9M shares outstanding; covering them would take 12.0 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Behind SPY and its sector fund XLV over 1 year
1 month: −11.7% (SPY −1.6%, XLV +13.5%). 3 months: −10.2% (SPY −0.4%, XLV +15.5%). 1 year: +6.2% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: IDYA, SPY and XLV · as of 4 Nov 2026
35% of the way up its 52-week range
Closed at $32.36 on 4 Nov 2026: 24.2% below the 52-week high of $42.68 (25 Aug 2026) and 20.7% above the low of $26.81 (10 Jun 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Volume 2.1× its 30-session average on 4 Nov 2026
4 Nov 2026 volume of 2.0M shares was 2.1× the average of the 30 sessions before it (946.5K), as the price rose 3.3%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−11.7%

6 months+12.6%

1 year+6.2%

5 years+36.1%

Newswire

About

Website

Notable moves

April 24, 2023
+35.70%
September 12, 2022
+30.70%
August 15, 2022
−34.82%

Newswire

About

Website

Notable moves

April 24, 2023
+35.70%
September 12, 2022
+30.70%
August 15, 2022
−34.82%

IDEAYA Biosciences, Inc.

IDEAYA Biosciences, Inc. in brief

Below its 50- and 200-day averages

12.0 days to cover short interest

Behind SPY and its sector fund XLV over 1 year

35% of the way up its 52-week range

Volume 2.1× its 30-session average on 4 Nov 2026

IDEAYA Biosciences, Inc.

IDEAYA Biosciences, Inc. in brief

Below its 50- and 200-day averages

12.0 days to cover short interest

Behind SPY and its sector fund XLV over 1 year

35% of the way up its 52-week range

Volume 2.1× its 30-session average on 4 Nov 2026